Final results of the SPECTRE study: real-world data giving an insight into the treatment of migraine patients with erenumab in Germany (P12-12.011)

The aim of the SPECTRE study was to collect real-world evidence to analyze patient profiles and understand treatment with the calcitonin gene-related peptide (CGRP)-receptor antagonist erenumab in Germany based on migraine characteristics and comorbidities.